Raphael Pharmaceutical Stock Cash And Equivalents
RAPH Stock | 0.26 0.00 0.00% |
Raphael Pharmaceutical fundamentals help investors to digest information that contributes to Raphael Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Raphael OTC Stock. The fundamental analysis module provides a way to measure Raphael Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Raphael Pharmaceutical otc stock.
Raphael |
Raphael Pharmaceutical OTC Stock Cash And Equivalents Analysis
Raphael Pharmaceutical's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Raphael Pharmaceutical has 0.0 in Cash And Equivalents. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Cash And Equivalents (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Raphael Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.Raphael Pharmaceutical is currently under evaluation in cash and equivalents category among its peers.
Raphael Fundamentals
Return On Asset | -19.04 | |||
Shares Outstanding | 15.62 M | |||
EBITDA | (1.63 B) | |||
Net Income | (1.62 B) | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (1.42 M) | |||
Market Capitalization | 17.19 M | |||
Total Asset | 422 K | |||
Net Asset | 422 K |
About Raphael Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.